skip to Main Content

Life Sciences Ontario publishes first substantial benchmarking data for sector’s performance

LSO Building Blocks

If you work in the life sciences in Ontario, your wages are approximately 26.5 per cent higher than those of the provincial average. On the other hand, if you’re a recent science graduate, you’re facing a challenging unemployment rate of 18.9 per cent.

These are only two of the data points described in the Life Sciences Ontario (LSO) Sector Report 2015, which is the first of its kind to provide well-defined data that clearly measure and report on the sector’s benchmarking and its economic contributions. It also gives policymakers evidence-based data to benchmark Ontario’s performance, such as approximately 83,000 highly skilled workers, against other North American jurisdictions.

MaRS Innovation is a member of the LSO, which has also published an infographic summarizing the 2015 sector report’s findings. This announcement was covered in BetaKit.

“In the past, making accurate comparisons was virtually impossible due to inconsistencies in both data and methodologies,” says Jason Field, LSO’s president and CEO. “As the voice for the life sciences community, it’s our role to research and publish a report that would substantially quantify and articulate the sector’s impact. We want to help Ontario’s life sciences sector reach its full economic and social potential, which will benefit all Ontarians. Producing a sector report to establish a baseline and help inform policy decisions is a key milestone in that process.”

Some of the report’s highlights include:

  • Ontario’s Life Sciences generates approximately $40 billion in annual revenues.
  • That revenue translates to approximately $38.5 billion in total contributions to Ontario’s Gross Domestic Product (GDP).
  • The life sciences employ approximately 83,000 highly-skilled workers at more than 5,600 establishments in Ontario.
  • Ontario’s sector ranks among the top clusters in North America (top ten by employment and top three by establishments).
  • The sector’s job growth outpaced the provincial average by nearly 10 per cent between 2001 and 2013, showing resilience during the 2008 economic downturn.
Continue Reading

Business Without Borders highlights ScarX Therapeutics’ Chinese co-development partnership

ScarX logoScarX Therapeutics, a spin-off company created by MaRS Innovation and The Hospital for Sick Children (SickKids), was profiled by Business Without Borders on September 25, 2012.

Sean Fine‘s article examines the strategic funding partnership MI pursued with NovoTek Therapeutics Inc. (NovoTek) in China to develop the anti-scarring cream, which was discovered by researchers at SickKids.

A multibillion-dollar market may await ScarX, a Toronto biomedical start-up, but first it had to figure out how to finance the development of its unique cream that reduces scarring after surgery.

Its answer to the shortage of Canadian venture capital in life sciences turned out to be a partnership with a drug company in China.

Continue Reading

VP Joel Liederman’s Financial Post article on mitigating innovation risk

Joel Liederman, vice-president (physical sciences)
Joel Liederman, MI’s vice-president of business development and physical sciences

MaRS Innovation’s Vice-President of Business Development and Physical Sciences Joel Liederman, has published an article in the Financial Post about strategies to mitigate risk within the innovation space.

The article, titled “Innovation Success Means Mitigating Risk,” is featured in the newspaper’s Productive Conversations section.

Continue Reading

Huffington Post Canada interviews Raphael Hofstein about Canadian venture capital shortage

Raphael Hofstein
Raphael Hofstein, president and CEO of MaRS Innovation

Raphael Hofstein, president and CEO of MaRS Innovation, was interviewed by Huffington Post Canada business reporter Rachel Mendleson for an article about Canada’s innovation gap and the shortage of Canadian venture capital:

One of the best ways to [raise venture capital], said Raphael Hofstein, President and CEO of Toronto-based MaRS Innovation, is to increase government investment, a lesson he learned while helping to create a life sciences early-stage fund in Israel several years ago.

“Everybody told us — institutions, industry — that they will not participate unless government has a piece of the pie. So governments have to participate, certainly in the early stage,” he said.

Continue Reading
Back To Top